Medicinal chemistry of competitive kainate receptor antagonists.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 3369727)

Published in ACS Chem Neurosci on December 10, 2010

Authors

Ann M Larsen1, Lennart Bunch

Author Affiliations

1: Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.

Articles cited by this

(truncated to the top 100)

Cloned glutamate receptors. Annu Rev Neurosci (1994) 10.58

Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol (1981) 6.70

Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron (2000) 6.22

Glutamate receptors at atomic resolution. Nature (2006) 3.26

A nomenclature for ligand-gated ion channels. Neuropharmacology (2008) 2.93

Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin A. Neuron (1993) 2.78

A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature (1997) 2.74

Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice. Nature (1998) 2.72

Crystal structures of the GluR5 and GluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity. Neuron (2005) 2.65

Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev (1993) 2.45

Kainate receptors are involved in synaptic plasticity. Nature (1999) 2.43

Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) (2005) 2.25

Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem (1992) 2.21

Roles and rules of kainate receptors in synaptic transmission. Nat Rev Neurosci (2003) 2.11

2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science (1990) 2.01

The KA-2 subunit of excitatory amino acid receptors shows widespread expression in brain and forms ion channels with distantly related subunits. Neuron (1992) 1.97

Glutamate receptor channels in rat DRG neurons: activation by kainate and quisqualate and blockade of desensitization by Con A. Neuron (1990) 1.89

A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem (1989) 1.82

Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron (1992) 1.74

Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology (2008) 1.70

Kainate receptors. Cell Tissue Res (2006) 1.66

AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology (1998) 1.57

Molecular physiology of kainate receptors. Physiol Rev (2001) 1.55

AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat Neurosci (1999) 1.54

Kainate receptors: subunits, synaptic localization and function. Trends Pharmacol Sci (1999) 1.50

Silent glutamatergic synapses and nociception in mammalian spinal cord. Nature (1998) 1.46

The glutamate story. Br J Pharmacol (2006) 1.45

Neuropharmacology of AMPA and kainate receptors. Neuropharmacology (1999) 1.43

A glutamate receptor channel with high affinity for domoate and kainate. EMBO J (1992) 1.43

Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology (1996) 1.32

Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs (2009) 1.30

The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology (2008) 1.25

A comparison of excitatory amino acid antagonists acting at primary afferent C fibres and motoneurones of the isolated spinal cord of the rat. Br J Pharmacol (1987) 1.21

Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther (1997) 1.14

Distinct subunits in heteromeric kainate receptors mediate ionotropic and metabotropic function at hippocampal mossy fiber synapses. J Neurosci (2005) 1.14

Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci (2002) 1.12

Depressant actions of gamma-D-glutamylaminomethyl sulfonate (GAMS) on amino acid-induced and synaptic excitation in the cat spinal cord. Brain Res (1985) 1.12

Mechanisms of antagonism of the GluR2 AMPA receptor: structure and dynamics of the complex of two willardiine antagonists with the glutamate binding domain. Biochemistry (2009) 1.12

Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology (2004) 1.11

Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J Med Chem (2003) 1.10

Is high extracellular glutamate the key to excitotoxicity in traumatic brain injury? J Neurotrauma (1997) 1.09

Molecular characterization of the human EAA5 (GluR7) receptor: a high-affinity kainate receptor with novel potential RNA editing sites. Receptors Channels (1994) 1.09

The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus. Neuropharmacology (1999) 1.08

LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia (2004) 1.08

Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology (1998) 1.07

Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res (1997) 1.07

Metabotropic regulation of intrinsic excitability by synaptic activation of kainate receptors. J Neurosci (2004) 1.07

Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6, and GluR7. J Neurosci (1999) 1.06

Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs (2000) 1.05

Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology (2004) 1.05

The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. J Mol Biol (2006) 1.04

Partial agonism and antagonism of the ionotropic glutamate receptor iGLuR5: structures of the ligand-binding core in complex with domoic acid and 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid. J Biol Chem (2007) 1.03

Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res (2007) 1.01

Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol (1995) 1.00

Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid. Mol Pharmacol (1996) 0.97

Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology (2008) 0.97

ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology (2008) 0.97

Involvement of neurotransmitters in the nucleus tractus solitarii in cardiovascular regulation. Physiol Rev (1992) 0.96

Glutamate in neurologic diseases. J Child Neurol (1997) 0.95

Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem (2005) 0.95

NMDA receptors in preBotzinger complex neurons can drive respiratory rhythm independent of AMPA receptors. J Physiol (2007) 0.95

Inhibition of kainate receptors reduces the frequency of hippocampal theta oscillations. J Neurosci (2007) 0.94

Upregulation of spinal glutamate receptors in chronic pain. Neuroscience (1996) 0.94

Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther (2006) 0.94

Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol Pharmacol (1996) 0.93

Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia. Neuropharmacology (1999) 0.93

Phosphono dipeptides and piperazine derivatives as antagonists of amino acid-induced and synaptic excitation in mammalian and amphibian spinal cord. Neurosci Lett (1984) 0.92

Competitive inhibition by NBQX of kainate/AMPA receptor currents and excitatory synaptic potentials: importance of 6-nitro substitution. Eur J Pharmacol (1992) 0.91

Mechanical allodynia in rats is blocked by a Ca2+ permeable AMPA receptor antagonist. Neuroreport (1999) 0.91

Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology (2007) 0.89

Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats. J Pharmacol Exp Ther (2006) 0.89

In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors. J Pharmacol Exp Ther (2004) 0.89

Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. J Med Chem (2007) 0.89

Selective block of recombinant glur6 receptors by NS-102, a novel non-NMDA receptor antagonist. Eur J Pharmacol (1994) 0.89

A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem (2001) 0.88

Kainate receptors and mossy fiber LTP. Neurotoxicology (2005) 0.87

Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J Med Chem (2002) 0.87

Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. J Med Chem (2005) 0.86

Chemistry, biological properties and SAR analysis of quinoxalinones. Mini Rev Med Chem (2006) 0.86

Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. J Med Chem (2006) 0.85

Kainate receptor agonists, antagonists and allosteric modulators. Curr Pharm Des (2002) 0.85

Parallel antagonism of synaptic transmission and kainate/quisqualate responses in the hippocampus by piperazine-2,3-dicarboxylic acid analogs. J Neurosci (1986) 0.85

Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br J Pharmacol (2003) 0.84

Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons. Eur J Pharmacol (1999) 0.83

(3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. J Med Chem (1993) 0.83

The novel antagonist 3-CBW discriminates between kainate receptors expressed on neonatal rat motoneurones and those on dorsal root C-fibres. Br J Pharmacol (2002) 0.83

In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology (1995) 0.82

Subtype selective kainic acid receptor agonists: discovery and approaches to rational design. Med Res Rev (2009) 0.81

Antagonist properties of a phosphono isoxazole amino acid at glutamate R1-4 (R,S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid receptor subtypes. Mol Pharmacol (1998) 0.81

The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg (2009) 0.81

Real-time measurement of ischemia-evoked glutamate release in the cerebral cortex of four and eleven vessel rat occlusion models. Brain Res (1998) 0.80

The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol Biochem Behav (1998) 0.80

Synaptic plasticity of kainate receptors. Biochem Soc Trans (2006) 0.80

GLUK1 receptor antagonists and hippocampal mossy fiber function. Int Rev Neurobiol (2009) 0.80

Molecular cloning, expression, and pharmacological characterization of humEAA1, a human kainate receptor subunit. J Neurochem (1994) 0.79

Stable expression of a functional GluR6 homomeric glutamate receptor channel in mammalian cells. Proc Natl Acad Sci U S A (1994) 0.79

Inhibitors of AMPA and kainate receptors. Curr Med Chem (2001) 0.79

Resolution, absolute stereochemistry, and enantiopharmacology of the GluR1-4 and GluR5 antagonist 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid. Chirality (1999) 0.78

Gamma-D-glutamylaminomethyl sulfonic acid (GAMS) distinguishes kainic acid- from AMPA-induced responses in Xenopus oocytes expressing chick brain glutamate receptors. Neuropharmacology (1993) 0.78

Changes in the extracellular levels of glutamate and aspartate during ischemia and hypoglycemia. Effects of hypothermia. Exp Brain Res (1998) 0.77

Articles by these authors

Review on modern advances of chemical methods for the introduction of a phosphonic acid group. Chem Rev (2011) 1.01

Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1. J Med Chem (2009) 0.92

Ibotenic acid and thioibotenic acid: a remarkable difference in activity at group III metabotropic glutamate receptors. Eur J Pharmacol (2004) 0.89

Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-Amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101). J Med Chem (2010) 0.84

Structure-activity relationship study of selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101) and absolute configurational assignment using infrared and vibrational circular dichroism spectroscopy in combination with ab initio Hartree-Fock calculations. J Med Chem (2012) 0.82

Heterocycles as nonclassical bioisosteres of α-amino acids. ChemMedChem (2013) 0.81

Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl)pentanedioic acid: a novel selective inhibitor of human excitatory amino acid transporter subtype 2. J Med Chem (2008) 0.80

Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7. J Med Chem (2008) 0.79

Pharmacological and structural characterization of conformationally restricted (S)-glutamate analogues at ionotropic glutamate receptors. J Struct Biol (2012) 0.79

Allosteric modulation of an excitatory amino acid transporter: the subtype-selective inhibitor UCPH-101 exerts sustained inhibition of EAAT1 through an intramonomeric site in the trimerization domain. J Neurosci (2013) 0.79

Design, synthesis and pharmacological characterization of coumarin-based fluorescent analogs of excitatory amino acid transporter subtype 1 selective inhibitors, UCPH-101 and UCPH-102. Bioorg Med Chem (2012) 0.79

Azetidinic amino acids: stereocontrolled synthesis and pharmacological characterization as ligands for glutamate receptors and transporters. Org Biomol Chem (2005) 0.78

Binding site and interlobe interactions of the ionotropic glutamate receptor GluK3 ligand binding domain revealed by high resolution crystal structure in complex with (S)-glutamate. J Struct Biol (2011) 0.78

Discovery of a new class of ionotropic glutamate receptor antagonists by the rational design of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid. ACS Chem Neurosci (2010) 0.76

Gram-scale solution-phase synthesis of selective sodium bicarbonate co-transport inhibitor S0859: in vitro efficacy studies in breast cancer cells. ChemMedChem (2012) 0.76

Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B. Org Biomol Chem (2014) 0.76

Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters. J Med Chem (2013) 0.76

Glutamate receptor agonists: stereochemical aspects. Curr Top Med Chem (2011) 0.76

Stereoselective chemoenzymatic synthesis of the four stereoisomers of l-2-(2-carboxycyclobutyl)glycine and pharmacological characterization at human excitatory amino acid transporter subtypes 1, 2, and 3. J Med Chem (2006) 0.75

Stereocontrolled synthesis and pharmacological evaluation of azetidine-2,3-dicarboxylic acids at NMDA receptors. ChemMedChem (2009) 0.75

Design and Synthesis of a Series of l-trans-4-Substituted Prolines as Selective Antagonists for the Ionotropic Glutamate Receptors Including Functional and X-ray Crystallographic Studies of New Subtype Selective Kainic Acid Receptor Subtype 1 (GluK1) Antagonist (2S,4R)-4-(2-Carboxyphenoxy)pyrrolidine-2-carboxylic Acid. J Med Chem (2016) 0.75

Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid. Neurochem Res (2014) 0.75

Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3. J Med Chem (2005) 0.75

Probing for improved potency and in vivo bioavailability of excitatory amino acid transporter subtype 1 inhibitors UCPH-101 and UCPH-102: design, synthesis and pharmacological evaluation of substituted 7-biphenyl analogs. Neurochem Res (2014) 0.75

Molecular recognition of two 2,4-syn-functionalized (S)-glutamate analogues by the kainate receptor GluK3 ligand binding domain. ChemMedChem (2014) 0.75

Rational design, synthesis and pharmacological evaluation of the (2R)- and (2S)-stereoisomers of 3-(2-carboxypyrrolidinyl)-2-methyl acetic acid as ligands for the ionotropic glutamate receptors. ChemMedChem (2011) 0.75

Binding mode of an α-amino acid-linked quinoxaline-2,3-dione analogue at glutamate receptor subtype GluK1. ACS Chem Neurosci (2015) 0.75